Professor Carla Treloar and Ms Annie Madden – Just approaches to delivering and measuring outcomes of hepatitis C treatment in a best-case scenario

Event type: 
Event date: 
Tuesday, 27 March 2018 - 1:00pm to 2:00pm
Berg Family Foundation Seminar Room, Level 6, Wallace Wurth Building, Kensington Campus, UNSW Sydney
Contact for inquiries: 
Rata Joseph, +61 (2) 9385 0900 or
Booking deadline: 

Kirby Institute Seminar Series presents

Professor Carla Treloar

Professor Carla Treloar

Director, Centre for Social Research in Health and Social Policy Research Centre, UNSW

Professor Carla Treloar's research interests are in the fields of hepatitis C and injecting drug use. She is a primarily qualitative researcher and is grounded in the disciplines of health and social psychology, public health and health policy. Her research encompasses the social aspects of drug use in relation to prevention of drug-related harms particularly blood-borne viruses, engagement of people who use drugs in health and other services, critical analysis of the structure and operation of services and societal attitudes towards drug use and people who use drugs.

Twitter: @carlatreloar

Ms Annie Madden

Ms Annie Madden

PhD Candidate/Community Engagement & Liaison Officer, Centre for Social Research in Health, UNSW

Annie Madden is a PhD Candidate and Community Engagement & Liaison Officer with the Centre for Social Research in Health and has her own consultancy business '2SqPegs Consulting'. Until March 2016, she was the CEO of the Australian Injecting & Illicit Drug Users League (AIVL) for 16 years.

Twitter: @Annie_Madden_


Australia leads the world in the provision of highly effective and very expensive hepatitis C treatments. Many other countries have imposed restrictions on who is eligible to receive treatments, based on disease status or use of alcohol and other drugs. This does not mean that the job is done in Australia or that we can rest on these achievements. We should continue to interrogate how hepatitis C treatments are delivered and what lens we use to measure the success of this investment. We will present the case for measures “beyond cure” using a new project on “patient reported outcome measures” of people who inject drugs considering and receiving hepatitis C treatment.